A Phase I Randomized Trial of Once‐Daily Versus Twice‐Daily Recombinant Human Parathyroid Hormone (1‐84) for Hypoparathyroidism

Recombinant human parathyroid hormone (1‐84), rhPTH(1‐84), is an approved adjunctive treatment to oral calcium and active vitamin D for adult patients with hypoparathyroidism; however, there is limited information on the effect of twice daily (BID) dosing of rhPTH(1‐84). This was a phase I, open‐lab...

Descripción completa

Detalles Bibliográficos
Autores principales: Ing, Steven W., Finkelman, Richard D., He, Ping, Khan, Aliya A., Mannstadt, Michael, Rejnmark, Lars, Song, Ivy, Takács, István, Wu, Yuna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2023
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10339078/
https://www.ncbi.nlm.nih.gov/pubmed/37457880
http://dx.doi.org/10.1002/jbm4.10758

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10339078/
https://www.ncbi.nlm.nih.gov/pubmed/37457880
http://dx.doi.org/10.1002/jbm4.10758

Ejemplares similares